News
Google News
Full Coverage

FDA panel votes 6-3 against AstraZeneca's camizestrant

Top news

CNBC

AstraZeneca stock falls after FDA panel votes against new cancer drug

By Elsa Ohlen
OncLive

FDA ODAC Votes Against Clinical Benefit of Switching to Camizestrant in HR+ Breast Cancer After ESR1 Mutation Detection

By Chris Ryan
Reuters

AstraZeneca shares dip after US regulatory panel rejects breast cancer drug

By Pushkala Aripaka
FirstWord Pharma

Voting against AstraZeneca's oral SERD, FDA panel points to lack of OS data

By Elizabeth Eaton

All coverage

Fierce Biotech

AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal

By Angus Liu
AstraZeneca

Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer

Endpoints News

FDA's oncology advisors vote against 'new paradigm' in AstraZeneca breast cancer trial

By Nicole DeFeudis
WSJ

AstraZeneca’s Breast-Cancer Candidate Drug Loses FDA Panel Vote

By Ian Walker & Joshua Kirby
Oncodaily

MinhTri Nguyen: Meaningful Negative Signal From The SERENA-6 ODAC Vote

MedPage Today

FDA Panel Gives Thumbs Down to Novel Strategy for Switching Breast Cancer Therapy

By Charles Bankhead
BioWorld News

Unique trial strategy muddies the ODAC waters for camizestrant

By Mari Serebrov
The Clinical Trial Vanguard

FDA Oncology Panel Rejects AstraZeneca’s Novel Trial Design Framework, 6-3

By Jon Napitupulu
pharmaphorum

FDA's ODAC delivers one loss, one win for AstraZeneca

BioSpace

AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

By Tristan Cesar Manalac
Oncology News Central

FDA’s Oncologic Drugs Advisory Committee Splits Vote on Breast and Prostate Cancer Drugs

By Youssef Rddad
GuruFocus

Guardant Health (GH) Experiences 4% Decline in Midday Trading

The Pharma Letter

Camizestrant faces split FDA panel vote despite strong Phase III data

Kalkine Media

AstraZeneca Setback Sparks Fresh FTSE 100 Debate

TipRanks

AstraZeneca: Buy Rating Reiterated as Camizestrant Upside and 18,000p Target Offset ODAC Setback

qz.com

AstraZeneca stock falls after FDA panel rejects breast cancer drug

By Colleen Cabili
marketscreener.com

FDA panel rejects risk-benefit profile of AstraZeneca cancer drug

Bloomberg.com

FDA Panel Votes Against Benefit of Astra’s Breast Cancer Drug

By Ashleigh Furlong & Jessica Nix
CancerNetwork

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

Targeted Oncology

FDA's ODAC Votes Against Camizestrant in Advanced Breast Cancer

By Sabrina Serani
parameter.io

AstraZeneca (AZN) Stock Slides After Mixed FDA Panel Verdicts on Cancer Therapies

ET Pharma

FDA panel rejects risk-benefit profile of AstraZeneca cancer drug

Yahoo Finance

AstraZeneca falls as FDA advisers reject breast cancer drug use

Benzinga

Why Is Guardant Health Stock Falling On Tuesday?

By Vandana Singh
Stock Titan

FDA panel opposes benefit-risk profile of AstraZeneca (AZN) camizestrant combo

Investing.com

FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer

CoinCentral

AstraZeneca (AZN) Stock Drops as Breast Cancer Drug Fails to Win Over FDA Advisors

Stocktwits

AZN Stock Rise As Wall Street Dismisses FDA Committee’s Rejection Of Breast Cancer Drug

By Anan Ashraf
富途牛牛

Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug

MSN

AstraZeneca shares drop after US regulators vote against breast cancer drug

Global Banking & Finance Review

AstraZeneca Shares Fall After US Panel Rejects Breast Cancer Drug

Fierce Biotech

FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting

By Angus Liu
Endpoints News

FDA revives oncology advisory panel to debate AstraZeneca drugs

By Max Bayer
Oncodaily

Matthew Kurian: ODAC Votes 6–3 Against Camizestrant Approval In SERENA-6

FirstWord Pharma

Biopharma bites: AstraZeneca's camizestrant under FDA's microscope, and more from Newron, Gilead, OSR

OncLive

FDA ODAC Live Updates: Committee Reviews SERENA-6 Data for Camizestrant in ESR1-Mutated, Hormone Receptor+ Breast Cancer

By Chris Ryan
Yahoo

FDA panel votes against backing AstraZeneca's breast cancer drug

marketscreener.com

AstraZeneca shares dip after US regulatory panel rejects breast cancer drug

By Pushkala Aripaka
Kalkine Media

AstraZeneca Faces Setback as Drug Review Stirs Market Focus

Reuters

AstraZeneca shares drop after US regulators vote against breast cancer drug

marketscreener.com

AstraZeneca shares drop after US regulators vote against breast cancer drug

Proactive financial news

AstraZeneca falls as FDA advisers reject breast cancer drug use

By Jamie Ashcroft & Oliver Haill
Proactive financial news

AstraZeneca falls as FDA advisers reject breast cancer drug use

By Jamie Ashcroft & Oliver Haill
Yahoo Finance UK

AstraZeneca falls as FDA advisers reject breast cancer drug use

marketscreener.com

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote -- Update

Investing.com Nigeria

AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant By Investing.com

By Vahid Karaahmetovic
FirstWord Pharma

Spotlight On: First-line and adjuvant opportunities still beckon for AstraZeneca's camizestrant despite FDA setback

Yahoo Finance

AstraZeneca’s Breast-Cancer Candidate Drug Loses FDA Panel Vote

By Ian Walker & Joshua Kirby
BioSpace

AstraZeneca’s breast cancer drug fails to earn backing of FDA advisory committee

By Tristan Cesar Manalac
Search
Clear search
Close search
Google apps
Main menu